Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.biospace.com › press-releases › alzamend-neuro-regains-compliance-with-nasdaqAlzamend Neuro Regains Compliance with Nasdaq Listing Standards

   www.biospace.com › press-releases › alzamend-neuro-regains-compliance-with-nasdaq

   • Zapisane w pamięci cache

   3 dni temu · About Alzamend Neuro. Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. ... 3 Biotechs Seek Over $700M in Renewed IPO Rush. September 13, 2024 · 2 min read · Annalee ...

2. ir.alzamend.com › news-events › press-releasesAlzamend Neuro Regains Compliance with Nasdaq Listing Standards

   ir.alzamend.com › news-events › press-releases

   • Zapisane w pamięci cache

   3 dni temu · In May 2024, the Panel granted Alzamend’s request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with the Equity Rule and satisfying all applicable requirements for continued listing on Nasdaq.

3. pl.investing.com › news › company-newsAlzamend Neuro ponownie spełnia wymogi Nasdaq dotyczące kapitału...

   pl.investing.com › news › company-news

   • Zapisane w pamięci cache

   4 dni temu · ATLANTA - Alzamend Neuro, Inc. (NASDAQ:ALZN), firma biofarmaceutyczna w fazie klinicznej, ogłosiła, że ponownie spełnia wymogi Nasdaq dotyczące kapitału własnego akcjonariuszy. Spółka, która pracuje nad terapiami na chorobę Alzheimera i inne zaburzenia psychiczne, otrzymała 14.10.2024 r. oficjalne powiadomienie od Nasdaq Stock ...

4. www.marketscreener.com › quote › stockAlzamend Neuro : Regains Compliance with Nasdaq Listing Standards...

   www.marketscreener.com › quote › stock

   • Zapisane w pamięci cache

   4 dni temu · Alzamend Neuro Regains Compliance with Nasdaq Listing Standards. ATLANTA, GA, October 15, 2024 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today ...

5. stockanalysis.com › stocks › alznAlzamend Neuro, Inc. (ALZN) - Stock Analysis

   stockanalysis.com › stocks › alzn

   • Zapisane w pamięci cache

   4 dni temu · Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million. Get a real-time Alzamend Neuro, Inc. (ALZN) stock price quote with breaking news, financials, statistics, charts and more.

6. ir.alzamend.comAlzamend Neuro, Inc. (ALZN)

   ir.alzamend.com

   • Zapisane w pamięci cache

   10 paź 2024 · Alzamend strives to provide hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.

7. www.businesswire.com › news › homeAlzamend Neuro - Business Wire

   www.businesswire.com › news › home

   • Zapisane w pamięci cache

   17 cze 2021 · Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million. June 17, 2021 04:30 PM Eastern Daylight Time.